BioCatalyst

Nivolumab Injectable Product, Trans-arterial tirapazamine embolization — catalyst calendar

1 verified catalyst event(s) referencing Nivolumab Injectable Product, Trans-arterial tirapazamine embolization, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-30
in 3mo
ESTIMATED
 READOUT
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Phase 2 · Hepatocellular Carcinoma, Gastric Cancer
 Teclison Ltd. Nivolumab Injectable Product, Trans-arte ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.